Sunesis Pharmaceuticals

US: SNSS

$43.5m market cap

$0.39 last close

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Investment summary

Sunesis recently presented a poster on the preclinical findings of its PDK1 inhibitor SNS-510. Surprisingly, researchers found that the drug was most active in cancer cell lines with mutations in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, with the strongest activity in melanoma, leukemia and brain cancers. Additionally, the company announced that this finding pointed to potential synergies with CDK4/6 inhibitors (such as Ibrance), which are now under investigation.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.7 (34.4) (35.5) (144.63) N/A N/A
2018A 0.2 (25.7) (26.6) (74.80) N/A N/A
2019E 0.0 (23.9) (24.0) (21.17) N/A N/A
2020E 0.0 (26.1) (26.5) (22.37) N/A N/A
Industry outlook

Sunesis is an oncology company with an early-stage asset with a validated target for the treatment of B-cell malignancies.

Last updated on 14/11/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 29.5
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (32.4) (49.9) (66.0)
Relative* (35.3) (54.0) (70.3)
52-week high/low US$1.7/US$0.2
*% relative to local index
Key management
William Quinn Chief Financial Officer and Senior Vice Presi

Content on Sunesis Pharmaceuticals